Skip to content

Second-opinion pathway: a statutory right, a regional routine, and one travel trap

16.1 The law, verbatim

The consolidated text of the Patient Act (Patientlag 2014:821) runs through SFS 2026:213. Its 8 kap. 1 § was last amended in 2019 and its 9 kap. 1 § in 2022 (Patientlag) [E].

8 kap. 1 § "En patient med livshotande eller särskilt allvarlig sjukdom eller skada ska få möjlighet att inom eller utom den egna regionen få en ny medicinsk bedömning. Patienten ska erbjudas den behandling som den nya bedömningen kan ge anledning till om 1. behandlingen står i överensstämmelse med vetenskap och beprövad erfarenhet, och 2. det med hänsyn till den aktuella sjukdomen eller skadan och till kostnaderna för behandlingen framstår som befogat."

Unofficial translation: "A patient with a life-threatening or particularly serious disease or injury shall be given the opportunity to obtain a new medical assessment within or outside his or her own region. The patient shall be offered the treatment that the new assessment may give rise to if 1. the treatment is in accordance with science and proven experience, and 2. having regard to the disease or injury in question and to the costs of the treatment, it appears justified."

The right applies only to region-run care. Under 1 kap. 2 §, this provision applies only to health care run by a region, which includes SUS, Karolinska and Akademiska. Commercial second-opinion services fall outside it.

Related provisions [E]:

  • The region's duty to provide the second opinion: Hälso- och sjukvårdslagen (HSL) 10 kap. 3 § requires the region to make it possible (HSL 2017:30).
  • The patient's right to be told: PL 3 kap. 2 § point 4 requires information about "möjligheten att få en ny medicinsk bedömning och en fast vårdkontakt" (the possibility of a new medical assessment and of a permanent care contact). PL 3 kap. 7 § requires that information to be given in writing if the patient asks.
  • A named contact: PL 6 kap. 2 § says a fast vårdkontakt "ska utses för patienten om han eller hon begär det" (shall be appointed if the patient requests it).
  • Choice of treatment: PL 7 kap. 1 § gives a choice between evidence-based alternatives, provided the choice is justified given the disease and its costs.
  • Choice of outpatient provider: PL 9 kap. 1 § allows a choice of publicly funded outpatient provider anywhere in Sweden.

16.2 Eligibility and who starts the process

Who qualifies. 1177 names cancer as an example of a qualifying disease. The decision on whether a case is "särskilt allvarlig" (particularly serious) still formally rests with the care provider (1177 Ny medicinsk bedömning) [E].

How it starts, according to 1177:

  • The patient raises it with the treating clinic.
  • "Den läkare som är medicinskt ansvarig för dig är skyldig att hitta en annan mottagning där du kan få en ny bedömning" (the doctor medically responsible for you is obliged to find another clinic where you can get a new assessment).
  • The patient "kan också själv ha förslag på en annan läkare eller mottagning" (may also propose another doctor or clinic), in Skåne or in another region.
  • The treating doctor then sends the referral.
  • Wanting a second opinion "behöver inte betyda att du är missnöjd" (need not mean you are dissatisfied).

[I] What the law does not give. It sets no deadline and no formal procedure, and it gives no right to a specific named doctor. No appeal route exists beyond the complaint channels.

16.3 Costs in 2026, and the travel-reimbursement trap

Who pays. The home region pays for the new assessment, for any new treatment it leads to, and for travel to another region (1177) [E].

Fees for 2026 (SKR fees 2026; Riksavtal 2025; 1177 Skåne fees) [E]:

  • Specialist visit: 200 SEK in Skåne. Out-of-region, the visiting region's fee applies, under the inter-regional agreement (Riksavtal) §8.7: 275 SEK in Stockholm and 260 SEK in Uppsala.
  • High-cost ceiling: outpatient fees, including those paid in other regions, are capped at 1,450 SEK per 12 months.
  • Other fees: a missed appointment costs 400 SEK (even with a free-care card), inpatient care costs 130 SEK per day for the first 30 days, and prescription drugs are capped at 3,800 SEK.

The trap. Region Skåne's binding travel rules (decided by the regional council on 8 April 2025) explicitly cover "resa till annan vårdgivare för förnyad medicinsk bedömning … så kallad second opinion" (travel to another provider for a renewed medical assessment, a so-called second opinion). But reimbursement requires all of the following (Skånetrafiken travel conditions) [E]:

  • A signed form. A Remiss/Betalningsförbindelse (referral and payment commitment) must reach Skånetrafiken. Only the head (verksamhetschef) of a public hospital unit can approve and sign it (Region Skåne, Vård i andra regioner, archived copy).
  • The right box ticked. The form must say "vård efter initiativ från Region Skåne" (care on Region Skåne's initiative), or care-guarantee or emergency care. Forms marked "patientens eget val", "fritt vårdval", "fritt vårdsökande" or "valfrihetsremiss" (patient's own choice, free choice of care, free care-seeking, choice referral) give no travel reimbursement.
  • Medical reasons and travel details. The form must state "medicinska skäl" (medical reasons), the mode of travel, and any need for accommodation or an escort.

Travel details (Skånetrafiken):

  • How to travel: by public transport or service vehicle. Driving your own car is reimbursed only with Skånetrafiken's prior approval.
  • Your share: a co-payment (egenavgift) of 34–204 SEK per trip, depending on distance. Travel costs are capped at 2,231 SEK.
  • Accommodation: reimbursed up to 4.5% of the price base amount (prisbasbelopp).
  • Booking: Skånetrafiken's travel service, 0771-77 17 73 or utomlansresor@skanetrafiken.se, weekdays 08–16. Alternatively, buy public-transport tickets yourself and claim afterwards.

16.4 Records and pathology material

What the referral must contain. The remiss doubles as the payment commitment. It must state the medical question and what has already been done, and it is valid for one year (Riksavtal 2.3) [E].

[I] What to ask for in the referral:

  • PAD numbers and block identifiers;
  • flow-cytometry reports;
  • laboratory history;
  • imaging reports, with digital transfer of the images.

[E] Give consent at the receiving clinic. The receiving out-of-region clinic may need J's consent to view Skåne's electronic records (1177 Välja vårdmottagning).

Pathology blocks follow Biobankslagen (section 3.6). Only the receiving institution can request them; J cannot carry them.

16.5 What happens afterwards

If the two teams agree, care continues in Skåne.

If the second team proposes a different treatment, Skåne must offer it, provided it is evidence-based and justified given the disease and its cost. This right is conditional. Where the treatment is given is the region's decision.

Inpatient care or a takeover of treatment by another region needs a referral approved in advance (SKR Riksavtal page).

[I] Timing. A second opinion does not pause the SVF care pathway, which can be transferred between regions. If treatment is indicated, J should ask that the plan keep moving in parallel.

Item Basis Status
Information about the diagnosis, options, the right to a second opinion and to a fast vårdkontakt; in writing on request PL 3 kap. 1–2, 7 §§ Legal right
A fast vårdkontakt if asked PL 6 kap. 2 §; HSL 4 kap. 2 a § Legal right
A named kontaktsjuksköterska and Min vårdplan VP8.2 §18.1; 1177 Guideline, not statute
The opportunity of a new medical assessment inside or outside Skåne PL 8 kap. 1 §; HSL 10 kap. 3 § Legal right; the provider judges whether the illness is serious enough
A specific hospital or doctor for the second opinion 1177: the patient "kan … ha förslag" (may make suggestions) Not a right
Region pays travel 1177; Riksavtal; Skåne travel rules Region rule; only if the form is marked as Region Skåne-initiated
Treatment recommended by the second opinion PL 8 kap. 1 § second paragraph Conditional legal right (evidence plus cost)
Free choice of outpatient provider anywhere in Sweden PL 9 kap. 1 §; HSL 8 kap. 3 § Legal right; own travel costs, no care guarantee there
Copies of records Tryckfrihetsförordningen (TF) 2 kap. 15–16 §§; GDPR Art. 15 Legal right
Pathology re-review; moving blocks Biobankslagen ch. 5 The process is regulated, but the biobank and clinicians decide
SVF lead times SVF v3.3 Guideline; not part of the care guarantee (vårdgaranti)
EEA care reimbursement Lag (2013:513) Legal right, capped at the Swedish cost

Sources: Patientlag; HSL; Biobankslag; Lag 2013:513; TF.

16.7 Step-by-step process

  1. Set up coordination. Ask the clinic to appoint a fast vårdkontakt or contact nurse and to activate Min vårdplan. Ask for written information about the diagnosis, the plan and his SVF status. (Legal right / guideline.)
  2. Collect the records (section 19). (Legal right.)
  3. Make the request. Tell the treating haematologist, or the contact nurse, that he wants a new medical assessment under PL 8 kap. 1 §. Propose a named team, for example the Karolinska or Uppsala CLL team (section 14.3). (Legal right; the choice of team is a request, not a right.)
  4. Check what the referral says. Ask that it includes the PAD numbers and all results, asks the receiving team whether it wants a haematopathology review of the slides or blocks, and arranges digital image transfer. (Regional practice.)
  5. Get the travel form right. Ask for a signed Remiss/Betalningsförbindelse marked as care on Region Skåne's initiative (ny medicinsk bedömning), not "patientens eget val", and stating medical reasons and the mode of travel. Make sure it reaches Skånetrafiken before booking. (Region rule.)
  6. At the receiving clinic, consent to electronic record access. Bring a timeline and your own copies. (Practical.)
  7. If refused or delayed:
  8. ask for the reason to be written into the record;
  9. escalate to the verksamhetschef;
  10. contact the Patient Advisory Committee (Patientnämnden), the independent statutory body in every region, or complain to IVO, the national health-care inspectorate. Providers "ska snarast besvara klagomål" (must answer complaints promptly). (Legal right; PL 11 kap.)
  11. Afterwards: if the teams differ, ask for a joint discussion and use PL 7 kap. 1 § (choice between evidence-based alternatives). (Conditional right.)
  12. Keep treatment planning moving in parallel if treatment is indicated. (Practical.)

16.8 Self-referral to another region: possible, but weaker

Karolinska [E] (Karolinska, out-of-region patients; Karolinska self-referral):

  • accepts a self-referral (egen vårdbegäran) through 1177 or Alltid Öppet, or on a paper form;
  • says a self-referral "bedöms på samma sätt som remiss från en läkare" (is assessed like a doctor's referral), with medical assessment and prioritisation within three working days;
  • describes its haematology unit as serving the Stockholm region, plus patients with "vissa sällsynta diagnoser från hela landet och utlandet" (certain rare diagnoses from the whole country and abroad) (Karolinska, Medicinsk enhet Hematologi).

Akademiska [E] (Akademiska Hematologmottagningen):

  • says "behöver du remiss" (you need a referral) but also offers egen vårdbegäran via 1177;
  • phone 018-611 43 30.

What SKR's compilation shows. Neither Stockholm nor Uppsala has a regional referral requirement for hospital haematology (August 2026). The receiving clinic still decides whether to accept.

The downsides:

  • the patient pays his own travel;
  • the visiting region's fee applies;
  • the care guarantee does not apply there;
  • it is not a formal ny medicinsk bedömning.

[S] A self-referral without the PAD, flow cytometry and genetics results is likely to be triaged slowly or sent back to primary care.

16.9 The Danish option (Rigshospitalet) and its limits

[I] No dedicated service is published. Rigshospitalet publishes no international-patient office or formal second-opinion service for foreign patients.

The general EU route, as described by the Danish national contact point (Styrelsen for Patientsikkerhed) [E]:

  • A doctor's referral is required.
  • The Danish region must give a date and place within eight weekdays, or say it lacks capacity.
  • Fees are charged, and a deposit or payment guarantee may be demanded.

Reimbursement from Försäkringskassan, afterwards (Försäkringskassan, planned care abroad; Lag 2013:513; 1177 Vård utomlands) [E]:

  • It is capped at what the care would have cost in Sweden, minus the Swedish patient fee, and can never exceed what was paid.
  • Travel and accommodation are not covered.
  • An optional advance ruling (förhandsbesked) fixes the minimum payout. The law requires a decision within 90 days of a complete application; Försäkringskassan aims for about three months.
  • Prior authorisation (förhandstillstånd, S2) is realistic only if the Swedish waiting time is not medically defensible.
  • Swedish patient insurance does not cover self-arranged care abroad.
  • Pathology material can go to Denmark only "för en viss åtgärd" (for a specified action), with the Skåne biobank's agreement.

Contacts:

  • Danish Patient Safety Authority: +45 7228 6600, stps@stps.dk
  • Försäkringskassan, private customers: 0771-524 524

Unverified. Rigshospitalet's willingness to accept such a referral, and its price, could not be confirmed. A 2012 article reported that it routinely turned away foreigners seeking specialised treatment, but that is too old to rely on (Altinget 2012, partial access).

[I] For a routine new diagnosis, the Danish route costs money, time and paperwork for no clear gain over Karolinska or Uppsala. A doctor-to-doctor consultation through the Swedish CLL leads, who already collaborate with Copenhagen, is more practical.